China's Healthcare Market is Expected to Grow as Government Changes Regulations - iCrowdNewswire
  • Spain
  • Brazil
  • Russia
  • France
  • Germany
  • China
  • Korea
  • Japan

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Nov 8, 2017 6:30 AM ET

China’s Healthcare Market is Expected to Grow as Government Changes Regulations

Disclosure NewswireTM

iCrowdNewswire - Nov 8, 2017



China’s healthcare market is projected to grow at an unprecedented CAGR of about 12% to reach $1 trillion by 2020, or up from $357 billion in 2011 as estimated in a recent report from McKinsey & Co. The government in China has decided to take major steps to improve the local healthcare infrastructure. A recent Bloomberg article emphasized the importance of a recent regulatory change of the Chinese government, according to which new rules will speed up approvals of medicines and medical devices, easing the process of introducing new treatments to the market. Shineco Inc (NASDAQ:  TYHT), Hutchison China MediTech Limited (NASDAQ: HCM), iKang Healthcare Group, Inc. (NASDAQ: KANG), BeiGene, Ltd. (NASDAQ: BGNE), Zai Lab Ltd. (NASDAQ: ZLAB

For years, local and multinational drug manufacturers have struggled with delayed approvals in China. Bloomberg’s report explains that a surging number of applications and a relatively small team of government reviewers resulted in a regulatory backlog. “For multinational and leading local innovative drugmakers, the anticipated acceleration of approval will improve patients’ access to new medicine and increase revenues for pharmaceutical companies,” said Jialin Zhang, senior healthcare analyst at ICBC International Research Ltd.

Shineco Inc (NASDAQ:  TYHT) announced breaking news this morning that, “a producer and distributor of Chinese herbal medicines, organic agricultural products, specialized textiles, and other health and well-being focused plant-based products in China, today provides further update on the status of establishing an apocynum industrial park in Xinjiang, China.

As we have previously disclosed on September 22, 2017, Shineco will operate the apocynum industrial park through its joint venture company, namely, Xinjiang Shineco Taihe Agriculture Technology Ltd. (“Xinjiang Taihe”). In compliance with the local regulations on apocynum harvest which regulate apocynum harvest for environmental concerns, Shineco has applied and received the Wild Apocynum Harvest Permit from the government of the Korla Region in Xinjiang, China. 2,000 workers will help Shineco harvest apocynum in the Tarim Basin Gobi Desert.

Authorized and supported by the local government, Shineco, Inc. plans to harvest 100,000 tons of apocynum straws beginning winter of 2017 until spring of 2018. It is a good start to establish an Apocynum Industrial Park and will set a solid foundation for Shineco’s business development and revenue growth in 2018. Shineco will also be helping 2,000 workers gain work placements with competitive salary in the local labor market, corresponding to the “poverty reduction” policy initiative that the Chinese government is actively promoting.

Mr. Yuying Zhang, Chairman and Chief Executive Officer of Shineco, stated, “We have long been committed to growing the apocynum industry in China, so we spared no effort in establishing an apocynum industrial park. We are excited that the comprehensive support from the local government has helped our business grow faster. With the promising development of Shineco’s business operation, we look forward to making more contributions to the apocynum industry and resolving local employment problems.”

Hutchison China MediTech Limited (NASDAQ: HCM), known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases. On October 31, 2017, the company has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel for the treatment in advanced gastric or gastroesophageal junction adenocarcinoma patients in China. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. This randomized, double-blind, placebo-controlled, multicenter trial is being conducted in patients with advanced gastric cancer who have progressed after first-line standard chemotherapy. 

iKang Healthcare Group, Inc. (NASDAQ: KANG) is one of the largest providers in China’s fast-growing private preventive healthcare space through its nationwide healthcare services network. iKang’s nationwide integrated network of multi-brand self-owned medical centers and third-party facilities provides comprehensive and high-quality preventive healthcare solutions across China, including medical examination, disease screening, outpatient service and other value-added services. In the fiscal first quarter ended June 30, 2017, iKang served a total of 1.41 million customer visits under both corporate and individual programs. On September 15, 2017, the company announced its unaudited financial results for the first quarter ended June 30, 2017. Net revenues were US$115.6 million, an increase of 14.2% year-over-year.

BeiGene, Ltd. (NASDAQ: BGNE) is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. Recently, the company announced that it will present data on its Bruton’s Tyrosine Kinase (BTK) inhibitor at the upcoming 59th American Society of Hematology (ASH) Annual Meeting. ASH will take place December 9-12, 2017 in Atlanta, GA.

Zai Lab Ltd. (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide. On September 29, 2017, the company announced that it has dosed the first patient in a Phase 3 registration trial to evaluate the safety and efficacy of ZL-2306 (niraparib) for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The Phase 3 trial is designed to evaluate ZL-2306 as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.

Please SIGN UP NOW at To Receive Alerts on Trending Financial News from all these companies. “The Latest Buzz in Financial News”

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, has not been compensated for financial news dissemination and PR services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: .

For further information:
[email protected]


Contact Information:

[email protected]

View Related News >